Stanford researchers have developed a novel gene therapy vector, AAV-capGL to overcome immune barriers that currently limit the efficacy and safety of adeno-associated virus (AAV)-based gene therapies.
Stanford researchers have developed an LVCTM3 system for producing lentiviral vectors and other viral particles, offering a cost-effective, simplified and scalable solution for various applications from gene therapy to vaccine development.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Stanford researchers in the Goldberg lab have developed a novel method for targeted gene therapy delivery to retinal astrocytes for the treatment of glaucoma and other optic neuropathies.
Stanford researchers have developed a new class of materials that enable new strategies for the efficient delivery of messenger RNA (mRNA) into cells and animals. The delivery materials are easily prepared (2 steps), stable and readily tuned.